BRPI0917440A2 - composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho - Google Patents

composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho

Info

Publication number
BRPI0917440A2
BRPI0917440A2 BRPI0917440A BRPI0917440A BRPI0917440A2 BR PI0917440 A2 BRPI0917440 A2 BR PI0917440A2 BR PI0917440 A BRPI0917440 A BR PI0917440A BR PI0917440 A BRPI0917440 A BR PI0917440A BR PI0917440 A2 BRPI0917440 A2 BR PI0917440A2
Authority
BR
Brazil
Prior art keywords
neoangiogenic
treatment
pharmaceutical compositions
eye disorders
ophthalmic pharmaceutical
Prior art date
Application number
BRPI0917440A
Other languages
English (en)
Inventor
Giuliano Francesco
Marrano Manuela
Mazzone Maria Grazia
Papa Vincenzo
Original Assignee
S I F I Societa Ind Farmaceutica Italiana S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S I F I Societa Ind Farmaceutica Italiana S P A filed Critical S I F I Societa Ind Farmaceutica Italiana S P A
Publication of BRPI0917440A2 publication Critical patent/BRPI0917440A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
BRPI0917440A 2008-08-08 2009-08-06 composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho BRPI0917440A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08425559A EP2156834A1 (en) 2008-08-08 2008-08-08 Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
PCT/EP2009/060197 WO2010015672A1 (en) 2008-08-08 2009-08-06 Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye

Publications (1)

Publication Number Publication Date
BRPI0917440A2 true BRPI0917440A2 (pt) 2015-12-01

Family

ID=39988813

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917440A BRPI0917440A2 (pt) 2008-08-08 2009-08-06 composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho

Country Status (8)

Country Link
US (1) US20110142923A1 (pt)
EP (2) EP2156834A1 (pt)
JP (1) JP2011530496A (pt)
CN (1) CN102164600A (pt)
BR (1) BRPI0917440A2 (pt)
MX (1) MX2011001455A (pt)
RU (1) RU2519739C2 (pt)
WO (1) WO2010015672A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
ES2847883T3 (es) * 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
CN103764118A (zh) * 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
CA2936239A1 (en) * 2014-01-16 2015-07-23 Ontogenesis, Llc Compositions and methods for the treatment of intraocular neovascularization and/or leakage
ES2905458T3 (es) * 2014-10-09 2022-04-08 Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L Formulaciones nanoestructuradas para la administración de silibinina y otros principios activos para el tratamiento de enfermedades oculares
WO2016176579A1 (en) * 2015-04-29 2016-11-03 Psivida Us, Inc. Injectable sustained release intraocular device
US20160324836A1 (en) * 2015-05-05 2016-11-10 pSivida US.Inc. Injectable depot formulations
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
WO2017027017A1 (en) * 2015-08-11 2017-02-16 Peregrine Ophthalmic PTE LTD. Stable liposomal formulations of carbonic anhydrase inhibitors for ocular drug delivery
GB2559162A (en) * 2017-01-27 2018-08-01 Univ Bradford Compound for use in medicine
CN112022848B (zh) * 2020-08-13 2022-02-22 中南大学湘雅二医院 索拉非尼在治疗1型糖尿病中的应用
WO2025169089A1 (en) 2024-02-05 2025-08-14 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL151833A0 (en) * 2000-03-24 2003-04-10 Novartis Ag Improved treatment of neovascularization
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MXPA06003164A (es) * 2003-09-23 2006-06-05 Novartis Ag Combinaciones de un inhibidor del receptor de vegf con otros agentes terapeuticos.
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
BRPI0618597A2 (pt) * 2005-11-14 2011-09-06 Bayer Healthcare Llc métodos de predição e prognóstico de cáncer e método de monitoramento de terapia contra o cáncer
EP1962842A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
JP2010506951A (ja) * 2006-10-17 2010-03-04 ダイアックス コーポレーション 連続的な併用療法

Also Published As

Publication number Publication date
JP2011530496A (ja) 2011-12-22
WO2010015672A1 (en) 2010-02-11
RU2011108578A (ru) 2012-09-20
EP2323657A1 (en) 2011-05-25
CN102164600A (zh) 2011-08-24
EP2156834A1 (en) 2010-02-24
RU2519739C2 (ru) 2014-06-20
MX2011001455A (es) 2011-04-14
US20110142923A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI1013377A2 (pt) formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
HUE061548T2 (hu) Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
PT2877184T (pt) Composições e tratamento para doenças e distúrbios oculares
BRPI0818799A2 (pt) Composições para o tratamento da doença de parkinson
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
PT2470191E (pt) Métodos e composições para prevenção ou tratamento de doenças oftálmicas
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0812755A2 (pt) Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BRPI0819105A2 (pt) composição para o tratamento e prevenção de edema de pálpebra
BRPI0822849A2 (pt) Aparelho para cirurgia oftalmológica
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
DK2148667T3 (da) Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL